Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

NCT05020704 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.

NCT NCT05020704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05020704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
Lead sponsor
NHS Greater Glasgow and Clyde
Phase
Phase 3
Overall status
Unknown status
Start date
September 16, 2022
Completion date
June 12, 2024
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction